692 results
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
15 May 24
Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations
8:30am
of Manufacturing. Notable achievements include overseeing the transition of Amgen’s manufacturing of the future program from R&D to Operations, the start-up
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
8 May 24
Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook
7:01am
of products as well as a decrease in our operational costs.
Research and Development (R&D) expenses, net in the first quarter of 2024 were $242 million … , an increase of 4% compared to $234 million in the first quarter of 2023, as we continued to execute on our Pivot to Growth Strategy. Our higher R&D expenses
8-K
EX-99.1
TEVA
Teva- Pharmaceutical Industries Ltd.
18 Apr 24
Regulation FD Disclosure
4:06pm
months ended
December 31,
September 30,
June 30,
March 31,
(Unaudited, U.S.$ in millions)
Revenues
Gross profit
R&D expenses
S&M expenses
G&A expenses … .$ in millions)
Revenues
Gross profit
R&D expenses
S&M expenses
G&A expenses
Other income
Segment profit*
International Markets Segment
Year endedDecember
8-K
EX-99.1
1wg8m5napvd85x4uz7lk
31 Jan 24
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
a2oq h4bb0bcnr
8 Nov 23
2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion
7:01am
8-K
EX-99.1
ikjkd121oxo9
4 Oct 23
Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
6:05am
8-K
EX-99.1
wqfqcf7sz344
2 Aug 23
Results of Operations and Financial Condition
7:00am
8-K
EX-99.1
pudpi um3
10 May 23
Results of Operations and Financial Condition
7:01am
CORRESP
aydwcrtp5vs krz7v
20 Dec 22
Correspondence with SEC
12:00am
8-K
EX-99.1
u7hmsfvb2be ufa
3 Nov 22
Key financial highlights and outlook
7:00am
CORRESP
8nkkx
26 Oct 22
Correspondence with SEC
12:00am